Cue Biopharma, Inc. (CUE)

Every figure this model derived for CUE, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 121,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 24,363,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 26,623,000 AssetsCurrent 2026-06-30
current liabilities 21,218,000 LiabilitiesCurrent 2026-06-30
equity 2,310,000 StockholdersEquity 2026-06-30
interest expense 57,000 InterestPaidNet 2026-06-30
ocf -50,046,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 37,654,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 26,029,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up CUE on one particular measure came for.

RatioValue
cash operating margin-189.29
current ratio1.25
current ratio reported1.25
dilution pct68.24
fcf margin-133.23
growth cv0.97
interest cover-1730.98
operating margin-262.03
owner earnings margin-202.36
revenue growth354.37
revenue growth per share170.08
rpo growth0.0
rule of 4092.34
sbc pct revenue69.13

What to be careful about

What this model itself distrusts about CUE's figures. Written by the derivation as it ran, not added afterwards.